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Major depressive disorder (MDD), is a common and severe mood disorder. Globally, ~ 300 
million people of all ages suffer from MDD (WHO 2021), which is the leading cause of 
disability in 2021. Approximately one third of the patients have inappropriate responses or no 
response at all to treatment. Even though some response is present, all available antidepressant 
drugs need to be administered for weeks or months to produce a meaningful clinical 
improvement. Therefore, finding novel and rapid-acting antidepressant treatments is a global 
priority. In this regard, the finding that ketamine –a dissociative anesthetic- had a rapid and 
sustained antidepressant effect in depressed people and the subsequent approval of intranasal 
esketamine for treatment-resistant depression (TRD) has changed the view of depression 
therapy from monoaminergic to glutamatergic drugs. It is postulated that ketamine's 
antidepressant activity results from its inhibition of the γ-aminobutyric acid (GABA) 
interneurons and the consequent disinhibition of cortical glutamatergic systems. 
 
Because selective activation of postsynaptic 5-HT1A receptors induces a rapid antidepressant 
response, it was thought that novel serotonin 5-HT1A receptor biased agonists could be one of 
such possible approaches. In the present work, we have studied the behavioral, biochemical and 
molecular aspects involved in the antidepressant-like effects of NLX-101 (formerly known as 
F15599). The results show that NLX-101 (0.16 mg/kg) reduced the immobility in the forced 
swim test when measured 30 min (albeit not 24 h and 7 days) after drug administration. 
Systemic administration of NLX-101 increased the extracellular concentration of dopamine and 
glutamate in the medial prefrontal cortex (mPFC). No changes were observed in the prefrontal 
output of noradrenaline and serotonin (5-HT). NLX-101 also produced a rapid increase in the 
synthesis of phospho-mTOR 30 min after drug administration. 
 
Altogether, our results suggest that NLX-101 has a rapid antidepressant-like response possibly 
by reducing the activity of GABA interneurons, thus disinhibiting the release of glutamate by 
the pyramidal neuron and increasing the production of phospho-mTOR. 




Major depressive disorder (MDD), is a common and severe mood disorder characterized by a 
pathologically low mood (hypothymia) and negative esteem about oneself, one's status in the 
real world, and one's future (Shadrina et al. 2018) that has a duration of two weeks or more. 
Globally, ~ 300 million people of all ages suffer from MDD (WHO 2021). MDD has a 
prevalence of 10% - 20% and is the leading cause of disability in 2021. In addition, MDD is 
the second leading cause of death due to suicide in 15-29-year-old people (WHO 2021). It is 
estimated that near 800,000 people die due to suicide every year. 
 
Different factors are involved in the development of this disorder, some are hereditary and some 
are stress-related factors. Indeed, repeated stress can induce a decrease in signaling of brain-
derived neurotrophic factor (BDNF) and mechanistic target of rapamycin complex 1 
(mTORC1) as well as loss of dendritic spines, which have been associated with the 
development of MDD. Also, different areas of the brain, such as hippocampus, cerebral cortex, 
amygdala, nucleus accumbens and hypothalamus are involved in the stress response and the 
pathogenesis of MDD. 
 
Despite the prevalence of the illness, the great majority of medications developed have been 
based upon the so-called monoaminergic hypothesis, thus increasing the level of monoamines 
in the brain. The first antidepressants that were developed around the 1950s were tricyclic 
drugs, which inhibit the reuptake of NA and/or 5-HT, thus increasing their synaptic availability, 
and augmenting their action on postsynaptic receptors (Harvey et al. 2010).  
 
Some years later, monoamine receptor antagonists and enzyme inhibitors were also developed 
as alternate mechanisms to enhance synaptic availability of monoamines (Di Giovanni et al. 
2016). The main enzyme inhibitors used were monoamine oxidase (MAO) inhibitors (MAOI). 
These compounds increase synaptic concentration of monoamines by inhibiting their 
metabolism. Tricyclic and MAOI antidepressant drugs were somehow effective in treating 
MDD. However, they also bear a bad profile of adverse effects that compromise adherence to 
treatment. For this main reason, further investigations lead to the development of drugs that 
selectively block the reuptake of serotonin (selective serotonin reuptake inhibitors [SSRIs] and 
selective noradrenaline reuptake inhibitors [SNRIs]). These drugs possess a better profile of 
adverse effects, which make adherence to treatment improved and therefore have been widely 
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and primarily used to treat MDD ever since.  
 
Other drugs, i.e the so-called atypical antidepressants were introduced later and had different 
mechanisms of action. For example, mianserin (antagonist of α1- and α2-adrenergic receptors) 
or trazodone (5-HT reuptake inhibitor and 5-HT2A receptor antagonist). 
 
Regardless of the widespread use of such different antidepressant drugs, all of them had the 
same problem, i.e. while the pharmacological effect was immediate, the therapeutic effect only 
appeared after chronic treatment that lasted weeks or even months. Furthermore, there is an 
important percentage of the population that do not respond to treatment, which is estimated to 
be approximately one third of the patients. Therefore, finding novel and rapid-acting 
antidepressant treatments is a global priority.  
 
In this regard, the finding that ketamine –a dissociative anesthetic- had a rapid and sustained 
antidepressant effect in depressed people and the subsequent approval of intranasal esketamine 
for treatment-resistant depression (TRD) has changed the view of depression therapy from 
monoaminergic to glutamatergic drugs. It is postulated that ketamine's antidepressant activity 
results from blockade of glutamatergic NMDA receptors in γ-aminobutyric acid (GABA) 
interneurons and the consequent disinhibition of cortical glutamatergic systems. In support of 
this mechanism of action it has been demonstrated that the administration of MK-801, another 
NMDA receptor antagonist similar to ketamine, predominately decreases the activity of 
putative GABA interneurons but, at a delayed rate, increases the firing rate of the majority of 





Figure 1. Ketamine blocks the NMDA receptor localized to GABA neurons, thus disinhibiting 
pyramidal, glutamatergic neurons (Krystal et al. 2019). 
 
 
            Ketamine as antidepressant 
  
Ketamine has recently revolutionized the field of pharmacotherapy of depression because it 
relieves symptoms rapidly (in 2 hours) and has a sustained effect that lasts 7 days. Ketamine is 
a blocker of the NMDA receptor of glutamate localized to GABA interneurons, which is 
postulated to reduce GABAergic input to pyramidal neurons, thus disinhibiting glutamatergic 
transmission in the prefrontal cortex. Blockade of these NMDA receptors raises BDNF levels 
and boosts AMPA glutamate transmission, thus enhancing synaptic efficacy. AMPA receptor 
activation activates a signaling cascade that raises BDNF levels. Local release of BDNF is 
thought to stimulate TrkB receptors, engaging relevant signaling cascades and resulting in the 
activation of the molecular target of rapamycin complex 1 (mTORC1). This step, in turn, 
activates local protein synthesis necessary for increasing dendritic spine formation and restoring 
synaptic connectivity (Krystal et al. 2019). 
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In experiments with rodents, ketamine reduces immobility and increases swimming behaviors 
in the forced swim test (FST), a predictive animal model of antidepressant-like effects 
(Castagné et al. 2011; López-Gil et al. 2019). From a biochemical viewpoint, ketamine 
increases the release of 5-HT, (Amargós-Bosch et al. 2006; López-Gil et al. 2019), 
noradrenaline (Lorrain et al. 2003), as well as glutamate (Moghaddam et al. 1997; López-Gil et 
al. 2019) in the mPFC. Interestingly, the rapid antidepressant-like effects of ketamine at 30 min 
after its administration does not appear to be dependent on serotonergic transmission as it occurs 
24 h after administration (Gigliucci et al. 2019). Unfortunately, ketamine has psychotomimetic 
adverse effects that compromise its therapeutic use. However, these adverse effects fade before 
the antidepressant effects emerge (Berman et al., 2000; Zarate et al., 2006). 
  
Inhibition of GABA in the PFC as rapid antidepressant mechanism 
  
GABA is the principal inhibitory neurotransmitter in the CNS and is opposed to the excitatory 
neurotransmitter glutamate. As an inhibitory neurotransmitter, GABA generates an inhibitory 
postsynaptic potential (IPSP) and causes hyperpolarization of the postsynaptic neuron while 
glutamate generates an excitatory postsynaptic potential (EPSP) and elicits depolarization of 
the postsynaptic neuron. A disruption in the balance between inhibition and excitation, or the 
glutamate-GABA equilibrium, could result in injury (e.g., strokes, Huntington’s disease), 
overexcitation (e.g., epilepsy, spastic disorders), or excessive inhibition (e.g., hypersomnia, 
benzodiazepine overdose) (de Leon et al. 2021).  
 
Therefore, the inhibition of cortical GABA transmission and the subsequent surge of glutamate 
transmission may be a relevant and novel strategy to achieve a rapid antidepressant response 
associated to the subsequent expression of the postsynaptic proteins involved in neuroplasticity 
and neurogenesis (Duman et al. 2016). 
  
 
Serotonin or 5-hydroxytryptamine 5-HT1A receptors 
  
Given the unwanted effects of ketamine, novel mechanisms that also reduce GABA 
transmission in the prefrontal cortex have been under scrutiny.  
Serotonin or 5-hydroxytryptamine 5-HT1A receptors are attractive targets for pharmacotherapy 
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of different pathologies associated with dysfunctional serotonergic neurotransmission, 
including anxiety, depression, Parkinson’s disease, pain and schizophrenia (Newman-Tancredi 
2011).  
 
5-HT1A receptors are expressed both as presynaptic autoreceptors on serotonergic cell bodies 
in the dorsal raphe nucleus and as postsynaptic heteroreceptors in multiple brain regions 
including the cortex, hippocampus, septum and hypothalamus. Interestingly, activation of 5-
HT1A autoreceptors in the raphe nuclei have pro-depressive effects (Richardson-Jones et al. 
2016; Bortolozzi et al. 2012), while stimulation of postsynaptic 5-HT1A heteroreceptors is 
necessary for the antidepressant action (Blier et al. 1997; Fukumoto et al. 2018).  
 
GABA interneurons of the prefrontal cortex bear a high density of 5-HT1A receptors (Santana 
et al. 2004) and their activation also enhances pyramidal cell firing (Lladó-Pelfort et al. 2012). 
Thus, stimulation of 5-HT1A receptors localized to prefrontal GABAergic interneurons are a 
promising alternative target to treat depressive states. Compounds that impact on these 
receptors, avoiding the stimulation of 5-HT1A autoreceptors, are called 5-HT1A biased (or 






















NLX-101 (also known as F15599) is a highly selective and efficacious ‘biased’ agonist at 
cortical 5-hydroxytryptamine 1A (5-HT1A) heteroreceptors preferentially activating Gαi versus 
Gαo G-protein subtypes. NLX-101 and also preferentially activates ERK1/2 phosphorylation. 
(Newman-Tancredi 2011). In rodents, NLX-101 possesses marked antidepressant-like activity, 
measured as suppression of immobility in the FST, albeit with a short duration of action. In 
addition, NLX-101 displays rapid-acting antidepressant-like effects in the rat chronic mild 
stress model (Depoortère et al. 2019). It is postulated that NLX-101 is able to inhibit GABA 
interneurons, thus increasing the release of glutamate in the synaptic cleft and stimulating the 






























General Objectives: To examine the cellular and molecular mechanisms responsible for the 





Objective 1. To assess the antidepressant-like effects of the intraperitoneal administration of 
0.16 mg/kg of NLX-101 in the FST and the novelty-suppressed feeding test (NSFT). 
  
Objective 2. To examine the release of noradrenaline, dopamine, serotonin, and glutamate in 
the mPFC after systemic administration of NLX-101. This will be done using in vivo 
intracerebral microdialysis coupled to ultra HPLC apparatus with electrochemical detection 
(Alexys®, Antec, The Netherlands). 
  
Objective 3. To study the intracellular signaling pathways coupled to the administration of these 













Male Sprague-Dawley albino rats of 240-260 g were used, maintained with light/dark cycles of 
12/12 hours (lights on at 07:00), 22 ± 1 °C and with free access to water and food.  
 
All experimental procedures were carried out in accordance with current Spanish legislation 
(RD 53/2013) and the Directive of the Council of the European Communities on "Protection of 
animals used for scientific purposes" of September 22, 2010 (2010/63/EEC) and were approved 






NLX-101 was generously donated by Neurolixis and dissolved in distilled water at the 
concentration of 0.16 mg/kg and injected in a volume of 5 ml/kg. Control rats were injected 
with distilled water in a volume of 5 ml/kg. 
  
 
Forced swim test 
  
The forced swim test (FST) evaluates the behavioral despair of the animal and has predictive 
validity to determine the antidepressant potential of a treatment. Rats were handled daily for 1 
week before FST for habituation.  
 
On day 1 (pretest), rats were placed in a clear plexiglas cylinder (46 cm height, 20 cm diameter) 
filled with 24 ± 1°C water to a height of 30 cm, for 15 min. After this pretest, animals were 
returned to their home cages and dried under a lamp for 30 min. Twenty-four hours after the 
pretest, rats received an i.p. injection of 0.16 mg/kg of NLX-101. Three tests were conducted 
30 min, 24 h and 7 days after drug administration in the same cylinder for 5 min. The test 
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sessions were videotaped (ANY-maze, Stoelting Europe, Dublin, Ireland) and the duration of 

















Figure 4. Forced swimming test. Outline of the three types of behavior that rats may exhibit 
during TNF (Cryan et al. 2002). 
 
 
Open field test 
  
To check for nonspecific changes in gross activity that would mask FST observations, 
locomotor activity was recorded for 15 min in an open field arena (100 cm × 100 cm × 40 cm) 
with gray plastic walls dimly lighted. Ambulatory behavior was video-tracked by a 













Concentric dialysis probes with a 4-mm membrane length were implanted under sodium 
pentobarbital anesthesia (60 mg/kg, i.p.) in the mPFC (AP +3.2 mm, L ±0.6 mm, DV -5.4 mm; 
from bregma), according to Paxinos and Watson (2007). In all cases, microdialysis experiments 
were conducted 24 h after surgery in freely moving rats by continuously perfusing probes with 
artificial cerebrospinal fluid (aCSF: 147 mM NaCl, 3 mM KCl, 1.2 mM CaCl2, 1.2 mM MgCl2) 
at a rate of 1.5 μl/min. Dialysate samples of 30 μl were collected every 20 min, and monoamines 
and glutamate were determined using an Alexys® Analyzer (Antec Scientific, Leiden, The 
Netherlands) following manufacturer’s methods. At the completion of dialysis experiments, 
rats were given an overdose of sodium pentobarbital and brains were processed for cresyl violet 



























To study protein expression after administration of NLX-101 i.p. (0.16 mg/kg), rats (n = 48) 
were sacrificed and divided in 4 groups: at 30 min, 1h, 2h after treatment. For each group, a 
control group was established to which the vehicle was injected (saline). Brains were then 
extracted, the mPFC was dissected on ice and stored at -80 °C.  
 
For cell lysate, mPFC samples were homogenized (1:15) in a solution composed of 10 mM 
HEPES (pH 7.9), 1.5 mM MgCl2, 100 mM KCl, and the following protease and phosphatase 
inhibitors: 1 mM phenylmethylsulfonyl fluoride (PMSF), 0.2 mg/ml aprotinin, 10 μg/ml 
leupeptin, 10 μg/ml pepstatin A, 10 μg/ml antipain, 10 μg/ml chemostatin, 1 mM Na3VO4 , 1 
mM NaF. To this, lysis buffer (1% Igepal®, 0.5% sodium deoxycholate, 0.1% SDS and 2.5 
mM CHAPS) was added and left 30 minutes in ice, then the solubilized proteins were collected 
in the supernatant after centrifuged for 10 min at 14000 rpm and 4 °C. 
 
The quantification was performed by the Lowry method (Lowry et al. 1951) and aliquots were 
prepared, to which was added loading buffer (Laemmli Sample Buffer, BIO-RAD, California, 
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United States) with β-mercaptoethanol at 5% and heated 5 minutes to 100 °C to denature the 
proteins, then put it on ice for 3 minutes and centrifuged for 5 minutes at 3000 rpm. Afterwards, 
supernatants were collected and aliquots were stored at -20 °C until used. For each sample, 55 
μg of protein (in duplicate) was loaded into discontinuous SDS-PAGE gels, consisting of a 
separation gel (10% or 15% acrylamide) depending on the molecular weight of the proteins to 
be analyzed and a packing gel (4% acrylamide). The gels were inserted into the electrophoresis 
cuvettes (Mini-PROTEAN® Tetra Cell, BIO-RAD, California, United States) with 
electrophoresis buffer and subjected to a current of 100 V for 15 minutes and 160 V for 50 
minutes until the molecular weight marker (PageRuler™ Plus Prestained Protein Ladder, 10 to 
250 kDa, ThermoFisher Scientific, Waltham, Massachusetts, United States) was observed to 
reach the limit of the gel. The proteins were then transferred to nitrocellulose membranes, 
immersed in a 20% methanol transfer buffer. Transfer conditions were constant voltage (100 
V) for 90 minutes at low temperature. The blockade of the nonspecific junctions was performed 
by incubating the membranes for an hour with 5% skimmed-milk powder and then incubated 
for one night at 4 °C with the primary antibodies diluted in 5% milk, to mark the following 
proteins: GluA1 subunit of glutamate AMPA receptor, postsynaptic density protein 95 (PSD-
95), Brain-derived neurotrophic factor BDNF, protein p11, PKB (Protein kinase B) Akt, 
extracellular signal‑regulated protein kinase ERK1/2, cAMP-response element binding protein 
CREB, β-arrestin 1, β-arrestin 2, mechanistic target of rapamycin mTOR, tubulin. 
 
The blockade of the nonspecific junctions was performed by incubating the membranes for one 
hour with skimmed milk powder at 3% + NAV/NAF inhibitors and then incubated for one night 
at 4 °C with the primary antibodies diluted in skimmed milk powder at 3% + NAV/NAF 
inhibitors, to mark the phosphorylated proteins. For a special protein such as CREB and 
pCREB, the blockade was performed by incubating the membranes for one hour with bovine 
serum albumin  (BSA) at 5% + NAV/NAF inhibitors and then incubated overnight at  4 °C with 
the primary antibodies CREB and pCREB, diluted in BSA at 5% + NAV/NAF inhibitors. 
 
The next day the membranes were washed with Tween 20 at 0.05% in salt Tris buffer (TBS-T) 
and incubated for one hour with conjugated secondary antibodies for fluorescent detection 
against IgG of mouse, rabbit or goat, at a concentration of 1:15,000, provided by Li-Cor 
Biosciences (Lincoln, NE, USA). After washing the membranes again with TBS-T, the 
fluorescence detection was carried out in an Odyssey CLx scanner and for the quantification 
the Image Studio Lite program was used, both from LiCor Biosciences (Lincoln, NE, USA). 
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Figure 7 . Western blot 1) Load protein sample 2) Apply current (current of 100 V for 15 
minutes and 160 V for 50 minutes) 3) Transfer proteins from the Gel onto membranes 4) 

















Table 1. Primary antibodies used for protein marking in western blot. List of antibodies used 
throughout the study, indicating the molecular weight of the band marked, the commercial 





 Statistical analysis 
  
Data are expressed as mean ± SEM. Differences between two groups were assessed by two-
tailed Student’s t-test. One or two-way analysis of variance (ANOVA) followed by post-hoc 
Tukey’s multiple comparisons test was used to analyze differences among three or more 
independent groups.  
 
For microdialysis experiments, changes in monoamines and glutamate concentrations were 
assessed by repeated measures ANOVA with drug and time as factors, followed by a post-hoc 





Forced swim test and open field test 
 
Two-tailed Student’s t-test of the forced swim test, show that IP administration of NLX-101 
(0.16 mg/kg) reduced the immobility of the court of rats when measured 30 min (albeit not 24 
h and 7 days) after drug administration (t=3,076, df=10; (p=0.0117)). 
 
 
Figure 8. Immobility of a court of 6 rats (type) in the forced swim test when measured 30 
minutes, 24 hours and 7 days later, after administration of NLX-101 (0.16 mg/kg). Reduced 
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immobility in the NLX-101 rats 30 minutes after IP administration. 
 
The results of the open field test showed no difference in locomotion during the 10 minute 
period. 
Figure 9. Open field test, total distance made by 5 rats, vehicle and NLX-101. No difference in 




Systemic administration of NLX-101 (0.16 mg/kg) increased the extracellular concentration of 
neurotransmitter dopamine and glutamate in the mPFC (Figure 10). In contrast, no changes 
were observed in the extracellular concentrations of noradrenaline and serotonin (5-HT).  
 
For glutamate, the results showed a significant effects of treatment [F(1,12)= 7,351 
(P=0,000005)], time [F(9,108)=4,311 (p=0,000083)] and the interaction treatment*time 
[F(9,108)=5,817 (p=0,000001)]. Post-hoc Tukey’s test showed that glutamate concentration in 
NLX-101-treated rats was higher than that of vehicle treated rats (*p < 0.0005). 
 
For dopamine, the results significant effects of treatment [F(1,11)= 7,1523 (P=0,021624), and 
the interaction treatment*time [F(9,99)=4,3049 (p=0,000096)]. As for glutamate, post-hoc 
Tukey’s test showed that dopamine concentration in NLX-101-treated rats was higher than that 









Figure 10. Systemic administration of NLX-101 increased the extracellular concentration of 
























Western blotting analyses were conducted 30 minutes, 1 hour, 2 hours and 6 hours after the 
administration of 0.16 mg/kg of NLX-101. 
 
The proteins analysed were Akt, mTOR, BDNF, ERK ½, CREB, PSD95, p11, Glua1 with their 
corresponding phosphorilated form. No change was observed in the non-phosphorylated forms 
(data not shown) and the corresponding measurements were done with the active 
(phosphorylated) forms. 
 
The systemic administration of NLX-101 (0.16 mg/kg) significantly increased the synthesis of 
pmTOR, pAkt, BDNF and pGluA1 although at different time points. The first proteins in 
elevating their levels were pmTOR and pGluA1 at 30 min and 1h, respectively (Fig. 12).  
 
BDNF and pAkt displayed a more delayed increase (Fig. 13), whereas pCREB and the β-
arrestins did not change up to a 6 h after NLX-101 administration (Fig. 14).  
 
pERK1/2, pGluA1, PSD95 and p11 showed a nonsignificant trend to increase their levels 30 



































































Figure 15. Systemic administration of NLX-101 showed a trend to increase the synthesis of 
pERK 1/2, p11 and PSD95. 
 
NLX-101 showed an increased expression of synthesis of pmTOR after 30 minutes and an 
increased expression of p(Ser845)GLUA1 after 1 hour of drug administration.  
 
Also, there is an increment in the BDNF and pERK ½ synthesis with a P of 0.0522 for BDNF 
and P=0.0526 for pERK ½ after 1 hour of drug administration, even if it is not significant.  
 
Therefore, IP administration of NLX-101 (0.16 mg/kg) showed increased expression of 
synthesis of pAkt and BDNF after 2 hours of drug administration as shown in Figure 13. P= 
0,0255 for pAkt and P=0,0623 and 0,0299 for BDNF. 
There has been an increment also in the level of synthesis of pERK ½ 2 hours after drug 
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administration.  P= 0.0562, even if it is not significant.  
 
IP administration of NLX-101 (0.16 mg/kg) showed increased expression of synthesis of pAkt 
ALSO after 6 hours of drug administration.  
 
PSD95 and p11 showed a nonsignificant trend to increase their levels only 30 minutes after 
drug administration, while no changes at all have been identified for pCREB, β-ARRESTIN 1 




In the present work we have described that NLX-101 showed rapid –at 30 min but not 24 h or 
7 days later- antidepressant-like effects in the FST associated with increased extracellular 
dopamine in the mPFC, as previously described (Lladó-Pelfort et al. 2010). The decreased 
immobility in the FST is not due to changes in locomotion as evidenced by a lack of effect of 
NLX-101 in the OFT.  
 
We also show that NLX-101 increases prefrontal glutamate release. Taken together, our results 
suggest that blockade of GABAergic interneurons in the mPFC by NLX-101 (Fig. 3) 
disinhibited pyramidal neurons projecting to dopaminergic neurons in the ventral tegmental 
area (VTA) eventually leading to an increased release of dopamine in the mPFC, NLX-101 
increased the release of dopamine in the mPFC. Interestingly, NLX-101 does not seem to 
disinhibit pyramidal neurons projecting to dorsal raphe nucleus and locus coeruleus as long as 
serotonergic and noradrenergic transmission in the mPFC was not altered. It is possible that the 
short-lasting increases in dopamine and glutamate (and the lack of effect on noradrenaline and 
serotonin) are responsible for the short-lived antidepressant-like effect of NLX-101 in the FST. 
 
In the present work we also described, for the first time, the intracellular signaling mechanisms 
involved in the antidepressant-like effect of NLX-101. Our results show that systemic NLX-
101 produced a rapid (in 30 min) increase in mPFC pmTOR. This is in line with the rapid 
increase of pmTOR observed after systemic ketamine (Li et al. 2010) and underscores the 
importance of mTOR signaling for obtaining a rapid antidepressant action. The most common 
upstream intermediaries of mTOR are Akt and ERK1/2. 
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However, the active form of Akt, pAkt, only increases 2 h after NLX-101 administration. On 
the other hand, pERK1/2 only exhibited a trend to be increased at 30 min after NLX-101 
administration, which is in line with previous work showing that ERK1/2 is activated at earlier 
(< 30 min) stages (Newman-Tancredi 2011).  
 
Furthermore, our results described a rapid increase in pGluA1, which together with the 
activation of downstream mTOR pathway, would suggest that GluA1 → mTOR pathway 
is the responsible for the rapid antidepressant response of N LX-101, as previously described 
for ketamine (Li et al. 2010). The apparent trend to an increased PSD95 would suggest the 
insertion of some proteins to the postsynaptic membrane, i.e. GluA1 and p11, and further 
support this view. 
 
On the other hand, BDNF showed a delayed increase of its synthesis, which supports the view 
that it may be involved in neuroplasticity changes perhaps related to a more sustained 
antidepressant effect of NLX-101. 
 
Altogether, our results suggest that NLX-101 has a rapid antidepressant-like response possibly 
by reducing the activity of GABA interneurons, thus disinhibiting the release of glutamate by 
the pyramidal neuron and increasing the production of pmTOR  and pGluA1. The increase in 
other factors such as BDNF and Akt seemed to occur in a more delayed time course and may 
be involved in a long-term modulatory effect in regulation of neurogenesis.  
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Figure 15.  Molecular mechanisms of some protein studies such as BDNF, mTOR, PSD95, 




Preferential targeting of cortical 5‐HT1A receptors is a particularly attractive strategy because it 
would accelerate the onset of therapeutic efficacy in depression. 
 
 In addition, preferential targeting of cortical 5‐HT1A receptors may increase the therapeutic 
margin with respect to side effects that arise from the activation of other 5‐HT1A receptor 
subpopulations (Newman-Tancredi 2011). 
 
The present results support this hypothesis. Unfortunately, the effects of NLX-101 are short-
lived. Therefore, further research is needed to develop new 5-HT1A biased receptor agonists 
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